170 related articles for article (PubMed ID: 10910044)
1. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
[TBL] [Abstract][Full Text] [Related]
2. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
3. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
4. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
5. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
6. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
[TBL] [Abstract][Full Text] [Related]
8. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
[TBL] [Abstract][Full Text] [Related]
9. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
11. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Lim HJ; Masin D; Madden TD; Bally MB
J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
[TBL] [Abstract][Full Text] [Related]
12. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
13. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
14. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
15. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
16. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL
Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
18. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
20. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
